Oxford Glycosciences and FDA to Study Proteomics of Toxicology

The collaboration is a Cooperative Research and Development Agreement struck with the FDA Center for Drug Evaluation and Research.

FDA researchers will develop models of drug-induced toxic injury to heart, vascular and liver tissue and will generate biological samples from these experiments. OGS scientists will use the company's proteomics techniques to analyze these samples and identify serum markers specific to toxic response.

Under the terms of a CRADA, the FDA shares resources, personnel, expenses, and expertise with private industry partners, but does not provide direct funding.

For more information, see the press release.